search
Back to results

A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults

Primary Purpose

Constipation

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
BLI-801
BLI-801
BLI-801
BLI-801
Sponsored by
Braintree Laboratories
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Constipation focused on measuring constipation, laxative

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female subjects at least 18 years of age
  • Constipated according to ROME I criteria
  • Otherwise in good health, as determined by physical exam and medical history
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse)
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
  • Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments for the duration of the study
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study
  • Subjects of childbearing potential who refuse a pregnancy test
  • Subjects who are allergic to any BLI-801 component.
  • Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

1

2

3

4

Arm Description

BLI-801 Dose 1

BLI-801 Dose 2

BLI-801 Dose 3

BLI-801 Dose 4

Outcomes

Primary Outcome Measures

Bowel Movement Count

Secondary Outcome Measures

Adverse events

Full Information

First Posted
December 20, 2007
Last Updated
September 24, 2009
Sponsor
Braintree Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT00583154
Brief Title
A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults
Official Title
A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults
Study Type
Interventional

2. Study Status

Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
April 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Braintree Laboratories

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To compare the safety and efficacy of BLI-801 administered at 4 dose levels in constipated adults.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation
Keywords
constipation, laxative

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
BLI-801 Dose 1
Arm Title
2
Arm Type
Experimental
Arm Description
BLI-801 Dose 2
Arm Title
3
Arm Type
Experimental
Arm Description
BLI-801 Dose 3
Arm Title
4
Arm Type
Experimental
Arm Description
BLI-801 Dose 4
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 1
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 2
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 3
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 4
Primary Outcome Measure Information:
Title
Bowel Movement Count
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Adverse events
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects at least 18 years of age Constipated according to ROME I criteria Otherwise in good health, as determined by physical exam and medical history If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse) Negative urine pregnancy test at screening, if applicable In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study Exclusion Criteria: Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments for the duration of the study Subjects who are pregnant or lactating, or intending to become pregnant during the study Subjects of childbearing potential who refuse a pregnancy test Subjects who are allergic to any BLI-801 component. Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John McGowan
Organizational Affiliation
Braintree Laboratories, Inc.
Official's Role
Study Director
Facility Information:
City
Anaheim
State/Province
California
Country
United States
City
Cranston
State/Province
Rhode Island
Country
United States
City
Cumberland
State/Province
Rhode Island
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults

We'll reach out to this number within 24 hrs